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Abstract: It is not known whether or not ward-specific antimicrobial use density (AUD) affects 
the ratio of methicillin-resistant Staphylococcus aureus (MRSA) in culture-positive S. aureus. A 
60-month study was attempted to ascertain the association between inpatient MRSA ratio and 
ward-specific AUDs as well as the former and latter study intervals, specimen types, and ward 
specialty. During the study, the professionals in infection control regulated the use of broad-
spectrum antimicrobials and those for MRSA. By both month and ward, the ratio of inpatients 
positive for MRSA to those positive for S. aureus was calculated. Factors associated with MRSA 
ratio included AUDs averaged for the sampling month and its previous month, outpatient MRSA 
ratio by age, ward specialty, specimen type, and half intervals to represent historical changes. Of 
a total of 4,245 strains of S. aureus isolated during the 5-year study, 2,232 strains (52.6%) were 
MRSA. By year, outpatient MRSA ratio at age $15 decreased in later years, as did inpatient 
MRSA ratio. Multivariate analysis for inpatient MRSA ratio revealed a positive risk in AUDs 
for meropenem (odds ratio [OR] 1.761; 95% confidence interval [CI] 1.761–2.637, P = 0.01), 
imipenem-cilastatin (OR 1.583; 95% CI 1.087–2.306, P = 0.02), ampicillin-sulbactam (OR 
1.623; 95% CI 1.114–2.365, P = 0.01), and minocycline (OR 1.680; CI 1.135–2.487, P = 0.01), 
respiratory care ward (OR 2.292; 95% CI 1.085–4.841, P = 0.03), and outpatient MRSA ratio 
(OR 1.536; 95% CI 1.070–2.206, P = 0.02). Use of broad-spectrum antimicrobials, such as 
meropenem, imipenem-cilastatin, and ampicillin-sulbactam may increase inpatient MRSA ratio. 
Ward factor should be included in MRSA surveillance because of the possible effect on AUD 
and considering patients’ backgrounds.
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Introduction
As a surveillance indicator of methicillin-resistant Staphylococcus aureus (MRSA), the 
inpatient ratio of MRSA in positive culture with S. aureus may be reduced by infection 
control within a hospital. The same ratio in outpatients, however, may show MRSA 
endemic in the region and thus can affect the inpatient MRSA ratio. Lee et al1 described 
that the susceptibility of S. aureus is associated with broad-spectrum antimicrobial use, 
an index of which is antimicrobial use density (AUD). Cheng et al2 described that AUD 
of broad-spectrum antimicrobials could measure the effect of an antimicrobial steward-
ship program. Alternatively, monthly AUD may represent an antimicrobial pressure in a 
unit, either within a ward or a hospital. However, the relationship among susceptibility 
of S. aureus, AUD, and inpatient ratio of MRSA remains unresolved.
Thus, a 60-month study was conducted retrospectively on a total of 22 antimicro-
bials with the objective to elucidate the association between MRSA prevalence and 
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ward-specific AUD as well as half intervals, the annual ratios 
of lower respiratory tract specimens, and ward specialty 
represented by respiratory care.
Material and methods
Infection control
Throughout January 2006 to December 2010, the infection 
control professionals regulated the use of broad-spectrum 
antimicrobials and agents for MRSA. They also submitted 
culture specimens for any suspicious infection and compli-
ance with contact precautions at weekly rounds across the 
wards. Surveillance culture specimens on the day of admis-
sion were regarded as those of outpatients. Hand hygiene 
measures were constantly observed by compliance to hand 
washing and the use of alcohol gel or non-sterile gloves.
Laboratory workup
In the laboratory, colonies growing on the blood agar 
medium were extracted onto MRSA Screen Agar (Japan 
Becton Dickinson, Tokyo, Japan). Colonies growing on this 
medium underwent the coagulase test (Rabbit Plasma Test; 
Eiken-kagaku, Tokyo, Japan), where positive strains were 
defined as S. aureus positive. Thereafter, strains of MRSA 
were defined using the Clinical and Laboratory Standards 
Institute:3 (1) having a minimum inhibitory concentration 
(MIC) of oxacillin equal or more than 4 µg/mL; or (2) 
having a MIC of cefoxitin equal or more than 8 µg/mL. 
Also, MRSA was defined as strains which showed MIC of 
oxacillin equal to 2 to 4 µg/mL and were positive for the 
penicillin-binding protein 2′ test (MRSA-LA; Denka Seiken, 
Niigata, Japan).
Inpatient strains of methicillin-sensitive and -resistant 
S. aureus underwent analysis of 50- and 90-percentile MIC 
(MIC50 and MIC90, respectively) for 13 agents.
Antimicrobial use density
Types of specimens positive for S. aureus were classified 
regardless of whether they were from the lower respiratory 
tract including sputum or the tracheal aspirate. Annual ratios 
of each type of specimen were calculated, which were later 
included in the data set.
AUDs were calculated for a total of 22 agents, 60 months, 
and specific wards using the formula:
AUD =   (Total antimicrobial dose)/ 
(DDD × Monthly inpatients) × 1,000  (1)
where DDD is the defined daily dose, as determined by 
the World Health Organization.4 The data on the monthly 
and ward-specific inpatients were provided by the hospital 
accounting office. For the data set, we entered the ward AUDs 
averaged for the month when the sample was submitted and 
for the preceding month. For example, the average value of 
AUD/pediatrics ward/2006-06/ampicillin and AUD/pedi-
atrics ward/2006-05/ampicillin was inputted into the AUD 
data for pediatrics ward/2006-06/ampicillin.
Antimicrobials subjected to AUD included: ampicillin, 
cefazolin, ceftazidime, cefmetazole, cefotiam, cefpirome, 
ceftriaxone, cefotaxime, cefozopran, clindamycin, flo-
moxef, fosfomycin, gentamicin, imipenem-cilastatin, lin-
ezolid, meropenem, minocycline, panipenem-betamipron, 
piperacillin, ampicillin-sulbactam, cefoperazone-sulbactam, 
and tobramycin.
Questionnaires to physicians
To help evaluate the presence or absence of cross infection 
among patients positive for MRSA, questionnaires (see 
supplementary material) were issued to physicians in charge 
of patients positive for MRSA upon first detection. At the 
physicians’ discretion, they reported the infectious status 
of their patients and estimates of propagation route, which 
were analyzed by dividing the 5 years into former and latter 
intervals. When a patient was found positive for MRSA and 
later admitted, the physician judged whether or not the patient 
was colonized with MRSA or was manifesting infection with 
MRSA (see supplementary material).
Statistical analysis
By the month and ward, patients with MRSA and all of those 
with S. aureus were counted without repetition to obtain 
their ratio. If no strains of S. aureus could be isolated in a 
month and a ward, the patient ratio was regarded as 0. The 
MRSA ratios were calculated separately for inpatients and 
outpatients; outpatients were further classified into younger 
than 15 years of age or older.
Factors associated with increased inpatient MRSA ratio 
included the averaged AUDs, half intervals, the annual ratios 
of the lower respiratory tract specimens, and the respiratory 
care and pediatrics wards. The pediatrics factor was included 
as an age indicator less than or equal to 15 years old for AUD. 
In the logistic regression analysis, AUD of any month above 
its median value was assigned 1 whereas AUD equal or 
less than its median value was assigned 0. Likewise for the 
remaining factors, a value of 1 was assigned when positive 
whereas a value of 0 was assigned when negative.
To each MRSA ratio of a particular month and a ward, the 
background factors above were added. Inpatient MRSA ratios 
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were age-adjusted to their outpatient counterpart separated 
at 15 years of age. Variables more or less than the median 
values were assigned 1 or 0, respectively. The data underwent 
univariate logistic regression analysis where outcome was 
determined as inpatient MRSA ratio higher than its median, 
which was assigned 1. Inpatient MRSA ratio less than its 
median was, however, assigned 0. Factors significant in uni-
variate analysis underwent subsequent multivariate analysis 
to exclude mutual confounding effect of background factors. 
For all statistical analyses, we used SPSS® (IBM Corpora-
tion; Armonk, NY, USA) and statistical significance was 
considered when P , 0.05.
At the admission of patients, informed consent was 
provided for their clinical and bacterial data use under the 
condition that their identifying information be omitted.
Results
Overview
A total of 30,536 microbes were isolated during the 5-year 
study period, including 23,566 from ten wards with a capacity 
of 419 beds and 6,970 from outpatient units. Among them, 
a total of 4,245 strains (13.9% of the grand total) of S. aureus 
were obtained, in which 2,232 strains (a ratio of 0.526 of 
all the S. aureus isolates) were MRSA from outpatients and 
inpatients (Table 1). A ratio of MRSA/S. aureus at 0.349 in 
outpatients was lower than in inpatients at 0.657. Of the 
2,232 cases of MRSA from outpatients and inpatients, 1,601 
(71.7%) were from inpatients. These included 433 patients 
(a ratio of 0.270) who had been positive as outpatients 
(Table 1).
The median ratio of MRSA-positive cases as outpatients/
MRSA-positive inpatients for the same patients was highest 
in the pediatrics ward at 0.589, whereas in respiratory care 
ward the ratio was 0.333, close to the ward’s subtotal (Table 1). 
Median inpatient MRSA ratio was the highest in respiratory 
care (a median of 0.787) but low in pediatrics (a median of 
0.348) and obstetrics/gynecology (a median of 0.400).
Of the 4,245 strains of S. aureus, 1,565 (36.9%) were 
derived from the lower respiratory tract, the ratios of which 
tended to decrease annually (Figure 1). As for outpatients, 
MRSA ratio for age #15 years (a median of 0.437) fluctu-
ated, whereas the ratio for age .15 years (a median of 0.309) 
decreased (Figure 1). Also, inpatient MRSA ratio showed a 
decreasing trend (Figure 1).
The MIC50 and MIC90 for 13 drugs in a total of 2,438 strains 
of S. aureus from inpatients showed minor time shift over for-
mer and latter study intervals (Table 2). For example, the MIC90 
of vancomycin increased from 1.0 to 2.0 µg/mL.
Antimicrobial use density
By agent, the median values of AUDs were high in cefazolin 
(19.25/patient), ampicillin-sulbactam (26.45/patient), and 
cefoperazone-sulbactam (8.39/patient). Annual trends of 
median values of AUDs fluctuated in AUDs with median 
values higher than 0 (Figure 2). By ward, the median AUD 
values were highest in the respiratory care ward using 
meropenem (12.66/patient) and ampicillin-sulbactam 
(103.52/patient), in the surgery ward using imipenem-
cilastatin (6.85/patient), and in the pediatrics ward with the 
use of minocycline (15.76/patient; Figure 3).
Table 1 Monthly number of patients positive for Staphylococcus aureus, those positive for methicillin-resistant S. aureus (MRSA), and 
inpatients having been positive for MRSA as outpatients (Outpt+) 
Location Major disciplines No of Outpt+/ 
MRSA/S. aureus
Ratio of  
Outpt+/MRSA
Ratio of  
MRSA/S. aureus
Beds
Outpatient units NA/631/1,807 NA 0.349
Wards
  Pediatrics Pediatrics 33/56/161 0.589 0.348 26
  3A Cardiovascular  
medicine-surgery
76/234/377 0.325 0.621 52
  3B Obstetrics/gynecology 0/4/10 0.000 0.400 20
  4A Neurosurgery 14/228/301 0.061 0.757 51
  4B Orthopedics 101/200/325 0.505 0.615 53
  5A Surgery 29/209/282 0.139 0.456 52
  5B Surgery/orthopedics 38/122/205 0.311 0.595 54
  6A Respiratory care 96/288/366 0.333 0.787 49
  6B Hematology/radiology 15/70/124 0.214 0.565 54
  ICU Intensive care unit 31/190/287 0.163 0.662 8
Wards subtotal 433/1,601/2,438 0.270 0.657 419
Total NA/2,232/4,245 NA 0.526
Note: Numbers are permitted for monthly repetition.
Abbreviations: MRSA, methicillin-resistant S. aureus; NA, not applicable; Outpt+, outpatients.
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Figure 1 Annual patient ratios of methicillin-resistant Staphylococcus aureus to S. aureus in outpatients #15 years old, in outpatients .15 years old, and in inpatients. For 
reference, the ratios of specimens derived from the lower respiratory tract are depicted. Lower respiratory tract and inpatient ratios show decreasing trends.
Abbreviations: Inpt, inpatient; LRT, lower respiratory tract; Outpt, outpatient; yo, years old.
Table  2  Minimum  inhibitory  concentration  of  50  percentile 
(MIC50)  and  of  90  percentile  (MIC90)  of  methicillin-sensitive 
and  -resistant  Staphylococcus  aureus  (n  =  2,438)  isolated  from 
inpatients
Drugs 2006/01–2008/06 2008/07–2010/12
Mina/MIC50/ 
MIC90/maxb 
(n = 1,233)
Min/MIC50/ 
MIC90/max 
(n = 1,205)
Arbekacin 0.5/0.5/1/16 1/1/1/8
Ampicillin-sulbactam 1/12/32/48 1/8/32/32
Cefazolin 1/32/32/32 1/32/32/64
Cefmetazole 4/16/64/64 4/16/64/64
Clindamycin 0.25/4/4/4 0.25/4/8/8
Fosfomycin 4/4/32/32 4/8/32/128
gentamicin 0.5/8/16/16 0.5/4/16/16
Imipenemc 1/4/16/16 1/2/16/16
Levofloxacin 0.25/4/8/8 0.12/4/8/8
Methicillin 0.25/4/4/4 0.25/4/4/4
Minocycline 0.5/0.5/16/16 0.5/0.5/16/16
Teichoplanin 1/1/2/4 0.5/1/1/8
Vancomycin 1/1/1/2 0.5/1/2/4
Notes: aMinimum MIC; bmaximum MIC; cwithout cilastatin by definition.
Abbreviations:  max,  maximum;  MIC,  minimum  inhibitory  concentration;  min, 
minimum.
Statistical analysis
Of the total 1,016 questionnaires, the physicians seeing 
patients with MRSA responded in 935 cases (92.0%) and 
899 cases (88.5%) for the infectious status and the propa-
gation route, respectively (Table 3A and B). Dividing the 
5 years into former and latter periods, the portion determined 
to be overt infection by MRSA and the portion estimated to 
be in-hospital propagation were comparable between the two 
periods by Pearson’s Chi-square test (both P . 0.05).
Of all the data for the 60 months and the ten wards for 
the analysis of AUD, univariate analysis for the higher 
MRSA ratio showed significance with 13 factors, nine of 
which were AUDs (Figure 4A). Subsequent multivariate 
analysis showed positive risk in AUDs for meropenem 
(odds ratio [OR] 1.761; 95% confidence interval [CI] 
1.761–2.637, P = 0.01), ampicillin-sulbactam (OR 1.470; 
CI 1.114–2.365, P = 0.01), imipenem-cilastatin (OR 1.583; 
CI 1.087–2.306, P = 0.02), and minocycline (OR 1.680; CI 
1.135–2.487, P = 0.01), respiratory care ward (OR 2.292; 
CI 1.085–4.841, P = 0.03), and outpatient MRSA ratio (OR 
1.536; CI 1.070–2.206, P = 0.02; Figure 4B).
Discussion
In order to investigate the possible cause of inpatient MRSA 
ratio, ward-specific AUD was defined to include the month 
of sample submission and its preceding month to represent 
the antimicrobial pressure in the ward. The multivariate 
analysis revealed significance in meropenem, imipenem-
cilastatin, and ampicillin-sulbactam among various AUDs, 
demonstrating their risk for increasing MRSA patient ratio. 
This effect by these antimicrobials was anticipated because of 
broad-spectrum activity. Indeed, Vernaz et al5 demonstrated 
that the use of these agents augmented MRSA incidence. 
Lee et al1 demonstrated that after hospital opening, increased 
AUD of broad-spectrum antimicrobials allowed rapid spread 
of MRSA. In our institute, however, we regulated the use of 
broad-spectrum antimicrobials such as carbapenems, which 
may have reduced the inpatient MRSA ratio. Likewise, 
MIC50 and MIC90 did not show noteworthy resistance for 
any antimicrobials. Our regulation of broad-spectrum agents 
may have kept the MIC constant over the study period.
Ampicillin-sulbactam, a beta-lactam with a beta-lactamase 
inhibitor, as well as carbapenems, were reported to retain 
useful activity;6 however, Bantar et al7 noted that rates of 
MRSA were inversely associated with the   consumption 
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index of ampicillin-sulbactam to the third-generation 
  cephalosporins. The discrepancy between the literature and 
our finding of the positive risk of ampicillin-sulbactam may 
be partially derived from the current multivariate analysis 
involving the ward factor.
A literature review has revealed several reports on the 
influence of AUDs on surveillance of S. aureus. Pros for 
AUDs’ influence stressed that AUDs of broad-spectrum drugs 
were associated with their drug resistance.8 Yoon and col-
leagues9 described that a proportion of resistance in S. aureus 
was correlated to penicillin use. Cons for AUDs’ influence, 
however, claimed that measures against cross infection more 
influenced the spread of S. aureus than did antimicrobial 
use.10 However, the factor of former and latter periods did 
not significantly influence MRSA inpatient ratio in our study. 
Thus, we presume that AUD control measures played a more 
crucial role in the reduction of inpatient MRSA ratio than 
did infection control measures. Therefore, excessive use of 
broad-spectrum agents is discouraged in the face of MRSA 
prevalence.
On the other hand, the reason why AUD of minocycline 
showed a positive risk for the inpatient MRSA ratio remains 
uncertain because the pediatrics ward, having had the high-
est AUD of minocycline, demonstrated the lowest inpatient 
MRSA ratio of 0.348. Indeed, Raad and colleagues11 reported 
that antibiotic lock with minocycline on the intravenous line 
may prevent catheter-related bloodstream infection with 
MRSA. However, Oshiro et al12 reported that minocycline 
antagonized the effect of vancomycin in S. aureus with het-
erogeneous resistance to vancomycin. Thus, further investiga-
tion may be warranted to solve this issue.
Another risk was the ward factor of respiratory care, 
which was selected for its highest MRSA ratio among all the 
wards. Borg and colleagues13 described that over-crowded 
general medicine wards triggered incidences of MRSA. 
Moreover, Kerttula and et al14 noted that patients in a long-
term care facility and health care ward shared similar MRSA 
genotypes. Likewise, our respiratory care ward admitted 
elderly patients referred from nursing homes, thus providing 
a background for increased MRSA ratio. Similarly, Kardas-
Sloma and colleagues15 described that the intensive care unit 
plays a role of incubator in the control of community-acquired 
MRSA. Their intensive care unit and our respiratory care 
ward may commonly serve as the interface between in and 
out of the hospital.
Eveillard et al16 described that admission at greater than 
80 years of age would increase the sensitivity of MRSA 
surveillance. Our preliminary study using outpatient MRSA 
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Figure 2 Annual trend of AUD in 22 agents. AUDs of ampicillin-sulbactam and 
cefazolin are high, but over time, like other agents, their AUDs fluctuate.
Note: Vertical axis shows the median values of AUDs.
Abbreviation: AUD, antimicrobial use density.
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(Respir) whereas AUD of imipenem-cilastatin (Imipenem-c) is highest in the surgery ward.
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ratio for all ages, however, showed no significance. Age 
adjustment, on the other hand, played a crucial role because 
pediatrics and adult patients demonstrated different MRSA 
ratios. Thus, both ward and age factors are to be given credit 
in the analysis of MRSA surveillance.
In the multivariate analysis, we omitted the factor of 
contact precaution because of its constant use. The aprons for 
barrier precaution had been made of fabrics during the study, 
only to be changed to plastic ones after the study. This might 
account for the lack of difference between the former and 
the latter periods in the questionnaires discerning the rates 
of hospital propagation of MRSA and infection.
The ward factor of pediatrics was not significant. This fac-
tor was included as an indicator of inpatients’ age adjustment 
because patients in this ward were 15 years old or younger. 
The reason why the MRSA ratio for outpatients #15 years old 
was fluctuating whereas the ratio for outpatients .15 years 
old decreased might derive from increased antimicrobial use 
and pediatrics MRSA reservoir in regional practitioners.17 
Future research may clarify age-specific mechanisms for 
MRSA surveillance in our region.
Conclusion
Broad-spectrum antimicrobials and outpatient MRSA ratio 
may increase inpatient MRSA ratio. Ward factor may be 
included in MRSA surveillance because of its confounding 
effect on AUD and patients’ background.
Disclosure
The authors report no conflicts of interest in this work.
Table 3 Questionnaires (n = 1,016) for (A) infectious status and (B) propagation route discerned by physicians in charge of patients 
positive for MRSA
2006/01–2008/06 2008/07–2010/12 Total
(A) Infectious status
Overt infection
  Not related to MRSA 125 (59.2%) 86 (40.8%) 211 (100.0%)
  Related to MRSA 179 (52.5%) 162 (47.5%) 341 (100.0%)
Colonization 128 (56.4%) 99 (43.6%) 227 (100.0%)
Undetermined 82 (52.6%) 74 (47.4%) 156 (100.0%)
No responsea 50 (61.7%) 31 (38.3%) 81 (100.0%)
Total 564 (55.5%) 452 (44.5%) 1,016 (100.0%)
(B) Propagation route
Imported from elsewhere 260 (51.1%) 249 (48.9%) 509 (100.0%)
In hospital 56 (60.2%) 37 (39.8%) 93 (100.0%)
Undetermined 165 (55.5%) 132 (44.5%) 297 (100.0%)
No responseb 83 (70.9%) 34 (29.1%) 117 (100.0%)
Total 564 (55.5%) 452 (44.5%) 1,016 (100.0%)
Notes: When a patient was once found positive for MRSA, the physicians judged whether the patient was colonized with MRSA or manifesting infection by the physical status 
and the clinical workup of the patient. a,bExcluding no responses, Pearson’s Chi-square tests do not show significance (aP = 0.40; bP = 0.18) in both series.
Abbreviation: MRSA, methicillin-resistant Staphylococcus aureus.
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Figure  4  (A)  Univariate  and  (B)  multivariate  logistic  regression  analysis  on 
the ward-specific antimicrobial use density (ampicillin through tobramycin) and 
other factors for the patient ratios of methicillin-resistant Staphylococcus aureus 
(MRSA)/S. aureus.
Notes: Diamonds indicate odds ratio; horizontal bar represents 95% confidence 
interval; *statistical significance (P , 0.05); **not available due to sample deviation.
Abbreviations:  LRT,  lower  respiratory  tract;  MRSA,  methicillin-resistant 
Staphylococcus aureus.
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Supplementary material
Questionnaire issued to physicians in charge of patients positive for methicillin-resistant Staphylococcus aureus. A   translation 
from the Japanese original.
A strain of MRSA was isolated from this patient. Please answer following questions.
Q1.  What was the specimen positive for MRSA?
A1.  Sputum/Tracheal tube/Decubitus/Drainage tube/Pus/Blood/Urine/Blood vessel catheter/Other (specify: )
Q2.  When did you submit the specimen?
A2. Year: , Month: , Day:
Q3.  What infectious status do you think patient was at submission?
A2.  (1)   Manifest infection, if so, specify: Due to MRSA/Due to MRSA and other(s)/Causality unknown either MRSA or 
other(s)
(2) MRSA colonization
Q4.  Where do you think MRSA was acquired?
A4.  Imported from community/Within hospital/Unknown
Q5.  Was the patient postoperative?
A5. Yes (specify operation date: )/No
Q6.  What was the main diagnosis of the patient? In what ward was the patient?
A6.  (specify diagnosis and ward: )
Q7.  Please give comments, if any.
A7.  (describe: )
Thank you for your cooperation.
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